Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed Inc. has demonstrated substantial promise in its clinical trials for Neflamapimod, particularly with improvements in cognitive and functional outcomes among patients with DLB, further validated by strong biomarker signals from previous studies. The incorporation of Neflamapimod into the UK EXPERTS-ALS platform highlights its potential as a prioritized therapy for ALS, alongside favorable tolerability and positive efficacy signals observed in over 800 participants during earlier trials. The new controlled manufacturing process enhances product consistency and stability, which may elevate plasma drug levels and potentially increase the likelihood of clinical success while maintaining a clean safety profile.

Bears say

CervoMed Inc faces significant market competition from both established and emerging therapies targeting similar neurological disorders, which may hinder its ability to penetrate and price effectively in the market. As a clinical stage biotechnology company, CervoMed has not yet generated any revenue from marketable products and has experienced continuous financial losses since its inception, raising serious concerns regarding its sustainability. Additionally, potential delays in clinical development and regulatory approval processes could extend timelines and escalate costs, while challenges in marketing and commercialization could further threaten the overall success of its product candidate, Neflamapimod.

CervoMed Inc (CRVO) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 6 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.